GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Total Equity

BAX (Baxter International) Total Equity : $7,054 Mil (As of Mar. 2025)


View and export this data going back to 1961. Start your Free Trial

What is Baxter International Total Equity?

Baxter International's total equity for the quarter that ended in Mar. 2025 was $7,054 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Baxter International Total Equity Historical Data

The historical data trend for Baxter International's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Total Equity Chart

Baxter International Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,726.00 9,121.00 5,895.00 8,468.00 7,024.00

Baxter International Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,235.00 7,708.00 7,942.00 7,024.00 7,054.00

Baxter International Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Baxter International's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=25782-18758
=7,024

Baxter International's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=21304-14250
=7,054

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baxter International Total Equity Related Terms

Thank you for viewing the detailed overview of Baxter International's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxter International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Total Equity
Comparable Companies
WST HOLX COO ALGN SOLV ATR AVTR RGEN STVN MMSI ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 XPAR:DIM OCSE:COLO B XSWX:STMN
Traded in Other Exchanges
BAX:Mexico 1BAX:Italy 0QK8:UK BTL:Germany BTL:Germany B1AX34:Brazil BAX:Austria
Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Website
https://www.baxter.com
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Executives
Jeanne K Mason officer: CVP, Human Resources ONE BAXTER PARKWAY, DEERFIELD IL 60015
Joel T. Grade officer: EVP, Chief Financial Officer SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth officer: EVP, Group Pres, Kidney Care 1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul officer: EVP, Group Pres, Healthcare ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig officer: EVP, Group President, Pharm ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight officer: EVP, Group Pres, Medical ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler officer: SVP, Chief Quality Officer ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn officer: SVP, President, APAC ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver director
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Cathy R Smith director TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403
Patricia Morrison director ONE BAXTER PARKWAY, DEERFIELD IL 60015